This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
About
Dr Rod O’Day
Head of Ocular Oncology Research
Dr Rod O’Day is an ocular oncology and medical retina subspecialist. He leads CERA’s Ocular Oncology Research Unit.
Dr Rod O’Day
Head of Ocular Oncology Research
MBBS (Hons), LLB (Hons), BSc, FRANZCO
Dr Rod O’Day is an ocular oncology and medical retina subspecialist. He leads CERA’s Ocular Oncology Research Unit.
After completing his ophthalmology training in Melbourne, Dr O’Day completed two Fellowships – one in medical retina at the Royal Victorian Eye and Ear Hospital, and one in ocular oncology at Moorfields Eye Hospital in London.
Dr O’Day’s main research interests are clinical studies in the fields of adult and paediatric ocular oncology. He also works with scientists in laboratory-based studies and other medical specialists in trials of novel systemic therapies for eye cancers.
Key research questions
- Can we improve the ocular treatment of patients with uveal melanoma?
- Can we help community clinicians (optometrists and ophthalmologist) recognise the warning signs of a uveal melanoma earlier?
- Can new imaging technology better diagnose and monitor choroidal tumours?
Selected publications
Key collaborators
Selected publications
O’Day R, Flanagan JPM, Roelofs KA, McGuinness MB, van Wijngaarden P, Damato BE (2022). The MOLES system to guide the management of melanocytic choroidal tumours: can optometrists apply it? Clin Exp Optom.
O’Day R, Roelofs KA, Negretti GS, Hay G, Arora AK, Stoker I, Damato BE, Sagoo MS, Cohen VML (2022). Long-term visual outcomes after ruthenium plaque brachytherapy for posterior choroidal melanoma. Eye.
O’Day R, Pejnovic T, Isaacs T, Muecke J, Glasson W, Campbell W (2020). Australian and New Zealand study of photodynamic therapy in choroidal amelanotic melanoma. Retina 40(5):972-976.
Salehi O, van Wijngaarden P, Keel S, Foreman J, Dirani M, Damato B, O’Day R (2021). Estimating malignancy risk of melanocytic choroidal tumours detected in the Australian National Eye Health Survey. Clin Exp Optom.
Roelofs KA, O’Day R, Alharby L, Arora AK, Cohen VML, Sagoo MS, Damato B (2020). The MOLES system for planning management of melanocytic choroidal tumours: is it safe? Cancers (Basel) 12(5): 1311.
See more publications
Key collaborators
- Associate Professor Peter van Wijngaarden, Deputy Director and Head of Ophthalmic Neuroscience, CERA
- Dr Xavier Hadoux, Postdoctoral Research Fellow, Ophthalmic Neuroscience, CERA
- Professor Bertil Damato, Moorfields Eye Hospital, London
Leave a direct enquiry for CERA below!
Please note: Unfortunately we are not able to provide individual medical advice over email.
